&w=3840&q=100)
Cipla buys 20% stake in iCaltech to broaden respiratory device portfolio
The investment aligns with Cipla's strategy to strengthen its presence in the respiratory care space, particularly in the diagnostics segment. iCaltech, an ISO 13485 certified medical device company, is engaged in the design, development, manufacturing, and commercialisation of diagnostic products, with a core focus on respiratory applications.
Achin Gupta, Global COO, Cipla, said, 'Our decision to invest in iCaltech reflects Cipla's commitment to advancing respiratory diagnostics. As lung leaders with the aim to reduce the existing gap in the current ecosystem, our strategic funding will enable iCaltech to further expand and develop innovative devices.'
Cipla said the deal would enable it to partner with iCaltech in developing integrated healthcare solutions by leveraging synergies between pharmaceuticals and medical device technologies. Under the terms, iCaltech will continue to operate independently, while Cipla will hold 20 per cent voting rights post-investment.
iCaltech recorded a revenue of ₹6.7 crore in FY25, up from ₹4.19 crore in FY24 and ₹1.28 crore in FY23.
The acquisition is part of Cipla's broader focus on expanding its devices, diagnostics, and digital offerings, especially in its core respiratory portfolio.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NDTV
29 minutes ago
- NDTV
Malaria Cases On Rise In Delhi: Expert Shares Tips To Stay Safe This Monsoon
A rise in vector-borne diseases has been observed in Delhi this monsoon. According to recent data from the Municipal Corporation of Delhi (MCD), the national capital has recorded 124 malaria cases, the highest in the last decade. Additionally, a total of 277 dengue cases and 18 chikungunya cases have been reported so far. While both malaria and dengue can be dangerous and potentially fatal, malaria is more likely to cause severe illness and death globally. Malaria is a life-threatening disease caused by parasites. It is transmitted to humans through the bites of infected female Anopheles mosquitoes. Malaria is more prevalent in tropical regions due to the hot and humid weather conditions. A rise in malaria cases is typically observed during the monsoon season as increased humidity and stagnant water bodies provide ideal breeding grounds for mosquitoes. "Malaria is a mosquito-borne infection from Plasmodium species. The unprecedented rains, waterlogging, and poor sanitation are some of the factors that contribute to a surge in malaria cases at this time of year, every year. And unfortunately, it is the elderly and the children who are more likely to have complications because of all the malaria-related illnesses that spread in the rainy season," Dr. Monica Mahajan, Director - Internal Medicine, Max Healthcare. Symptoms of malaria Individuals infected with malaria may initially develop mild symptoms. Later, within 10-15 days of getting bitten by an infected mosquito, the following symptoms are commonly reported: Fever Chills Fatigue Headaches Muscle ache Chest pain Cough Seizures "Malaria typically presents as high-grade fever with shivering, with headache, body pains and along with that the complications of malaria can involve various systems of the body, including causing jaundice, brain involvement or kidney involvement," Dr. Mahajan added. Malaria can also cause severe illness, especially when left untreated. Infants, children under 5 years, pregnant women, and people with pre-existing health conditions are also at a higher risk of severe illness. Severe symptoms include: Extreme fatigue Impaired consciousness Breathing difficulties Dark-coloured urine Jaundice Abnormal bleeding In some cases, it may also cause brain damage, organ failure and even death. How to stay safe "Preventing mosquito bites and eliminating breeding grounds are two effective strategies for preventing malaria. Cover yourself up with full-sleeved clothes and trousers, use DEET-based mosquito repellents and avoid stepping out during peak hours." "Dengue, malaria, typhoid and jaundice are quite common during the monsoon. In case you have any high-grade fever in this rainy season, then definitely get yourself tested for malaria. Any high fever does not mean it is viral. It is of utmost importance that you visit the doctor, get the required blood tests done, and are started on the appropriate medication," Dr. Mahajan added. "If malaria is not treated on time, it can be fatal. So it is important that we keep in mind that this is the rainy season, malaria cases are on the rise, and every fever needs to be monitored consciously," she advised. Other than mosquito bites, blood transfusions or use of contaminated needles may also transmit malaria.
&w=3840&q=100)
Business Standard
29 minutes ago
- Business Standard
GPT Infraprojects rallies 9% as Q1 profit zooms 40% YoY; declares dividend
GPT Infraprojects share price: Construction engineering firm GPT Infraprojects shares were in demand on Tuesday, August 8, 2025, with the stock rising up to 9.41 per cent to an intraday high of ₹141.25 per share. At 11:41 AM, GPT Infraprojects shares continued to trade higher, up 6.78 per cent at ₹137.85 per share. In comparison, BSE Sensex was trading 0.39 per cent lower at 80,700.25 levels. Why did GPT Infraprojects share price rally? GPT Infraprojects shares zoomed after the company reported a string set of results in the June quarter of financial year 2026 (Q1FY26). GPT Infraprojects reported a 32.2 per cent year-on-year jump in standalone total income at ₹316 crore, driven by strong execution in its infrastructure business and continued momentum in the concrete sleeper segment. Standalone Ebitda rose 21.5 per cent YoY to ₹41.8 crore, while net profit grew 29.1 per cent to ₹22.6 crore. Segment-wise, the infrastructure division remained the key revenue driver, contributing ₹299.6 crore, or 92 per cent of total operating income, in Q1FY26. This segment delivered healthy margins, exceeding internal Ebitda benchmarks, on the back of solid execution across major projects. The sleeper segment recorded revenue of ₹10.2 crore, supported by stable Indian operations and contributions from South Africa, although the rest of the Africa business remained subdued during the quarter. 'The Government's continued focus on infrastructure development presents a robust opportunity for growth, and we remain confident in our ability to expand into newer geographies while delivering world-class infrastructure for the nation. We have commissioned a Steel Girder and Components Manufacturing Facility at West Bengal, with an initial capacity of 10,000 MT per annum with provisions to enhance the final capacity to 25,000 MTPA over a period of 2 years. Order Execution is going on smoothly while we maintain the Ebitda hurdle rate. The strong numbers are not just milestones, they reflect disciplined execution, strategic clarity and the collective commitment of our people. We are now at an inflection point—a moment where decades of groundwork are converging into scalable, sustainable growth,' said Dwarika Prasad Tantia, chairman, GPT Infraprojects. GPT Infraprojects dividend The board also declared a first interim dividend of ₹1 per share, with the record date set for August 11, 2025. The company's order book stood at ₹3,569 crore, with fresh inflows worth ₹396 crore so far this fiscal, including additions to ongoing contracts. About GPT Infraprojects Incorporated in 1980, GPT Infraprojects is the flagship entity of the Kolkata-based GPT Group. A leading player in the infrastructure space, the company operates through two key segments – Infrastructure and Sleeper. Since its foray into the infrastructure sector in 2004, GPT has emerged as a key railway-focused EPC player, specialising in the execution of large-scale civil projects such as railway bridges and road overbridges (ROBs). In the Sleeper segment, GPT manufactures and supplies concrete sleepers for railway networks in India and select African markets. Its manufacturing facilities are strategically located in Panagarh (West Bengal), Ladysmith (South Africa), Tsumeb (Namibia), and Eshiem (Ghana).
News18
an hour ago
- News18
Highway Infrastructure IPO fully subscribed within hours of opening for bidding
New Delhi, Aug 5 (PTI) The initial public offer of Highway Infrastructure Ltd got fully subscribed within hours of opening for bidding on Tuesday. The three-day initial share sale received bids for 11,97,90,186 shares against 1,60,43,046 shares on offer, translating into 7.47 times subscription, according to data available with the NSE till 11:45 hours. Retail Individual Investors (RIIs) part fetched 9.63 times subscription while the quota for non-institutional investors got subscribed 7.14 times. The Qualified Institutional Buyers (QIBs) portion received 90 per cent subscription. Highway Infrastructure Ltd on Monday said it had raised Rs 23.40 crore from the anchor investors, including HDFC Bank and Abans Finance Pvt Ltd. The Rs 130-crore Initial Public Offering (IPO) will conclude on Thursday. The price band has been fixed at Rs 65-70 per share. The IPO is a mix of fresh issue of 1.39 crore shares aggregating to Rs 97.52 crore and an offer for sale of 46.4 lakh shares amounting to Rs 32.48 crore. Proceeds from the fresh issue to the tune of Rs 65 crore will be utilised to fund the working capital requirements of the company and the balance for general corporate purposes. Incorporated in 1995, Highway Infrastructure Ltd (HIL), is engaged in tollway collection, EPC (Engineering, Procurement, and Construction) projects, and real estate development. The Indore-based company specialises in the construction and maintenance of roads, highways, bridges, and residential projects. The company's total income stood at Rs 504.48 crore and profit after tax of Rs 22.40 crore. The company's shares will be listed on the BSE and NSE. Pantomath Capital Advisors is the sole book-running lead manager, while Bigshare Services is the registrar for the IPO. PTI HG HG DR DR view comments First Published: August 05, 2025, 12:00 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
